CSL logo

CSL - CSL Share Price

A$270.88 3.4  1.3%

Last Trade - 4:40am

Large Cap
Market Cap £68.86bn
Enterprise Value £71.62bn
Revenue £6.74bn
Position in Universe 5th / 1842
Unlock CSL Revenue
Relative Strength (%)
1m -7.64%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -22.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
5,628 6,115 6,923 7,915 8,539 9,151 10,120 10,866 +10.2%
+8.3 -17.6 +22.0 +39.9 +11.5 +8.4 -0.52 +10.9
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 30 June 2020, CSL Limitedrevenues increased 7% to $9.15B. Net income increased 10%to $2.1B. Revenues reflect CSL Behring segment increase of7% to $7.7B, Seqirus segment increase of 10% to $1.15B,United States segment increase of 16% to $4.6B, Rest of theworld segment increase of 14% to $2B. Net income benefitedfrom Foreign Exchange Gain/LossNon-Business decrease of 83%to $8.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for CSL
Graphical History


CSL Revenue Unlock CSL Revenue

Net Income

CSL Net Income Unlock CSL Revenue

Normalised EPS

CSL Normalised EPS Unlock CSL Revenue

PE Ratio Range

CSL PE Ratio Range Unlock CSL Revenue

Dividend Yield Range

CSL Dividend Yield Range Unlock CSL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CSL EPS Forecasts Unlock CSL Revenue
Profile Summary

CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products.

Last Annual June 30th, 2020
Last Interim June 30th, 2020
Incorporated April 1, 1991
Public Since June 8, 1994
No. of Shareholders: 205,293
No. of Employees: 27,000
Sector Healthcare
Industry Pharmaceuticals
Index S&P/ASX 50 , S&P/ASX All Ordinaries , S&P/ASX 20 , S&P/ASX 100 , S&P/ASX 200 , S&P/ASX 300 , FTSE Developed Asia Pacific , FTSE Developed Asia Pacific Ex Japan ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 454,048,707
Free Float (0.0%)
Eligible for
CSL Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CSL
Upcoming Events for CSL
Friday 12th February, 2021 Estimate
Half Year 2021 CSL Ltd Earnings Release
Frequently Asked Questions for CSL
What is the CSL share price?

As of 4:40am, shares in CSL are trading at A$270.88, giving the company a market capitalisation of £68.86bn. This share price information is delayed by 15 minutes.

How has the CSL share price performed this year?

Shares in CSL are currently trading at A$270.88 and the price has moved by -10.86% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the CSL price has moved by -7.51% over the past year.

What are the analyst and broker recommendations for CSL?

Of the analysts with advisory recommendations for CSL, there are there are currently 1 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for CSL is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will CSL next release its financial results?

CSL is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the CSL dividend yield?

The CSL dividend yield is 0.98% based on the trailing twelve month period.

Does CSL pay a dividend?

Last year, CSL paid a total dividend of 2.02, and it currently has a trailing dividend yield of 0.98%. Looking ahead, CSL has not announced an ex-dividend date yet.

When does CSL next pay dividends?

CSL has yet to annouce their ex-dividend date. The historic dividend yield on CSL shares is currently 0.98%.

How do I buy CSL shares?

To buy shares in CSL you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of CSL?

Shares in CSL are currently trading at A$270.88, giving the company a market capitalisation of £68.86bn.

Where are CSL shares listed? Where are CSL shares listed?

Here are the trading details for CSL:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: CSL
What kind of share is CSL?

Based on an overall assessment of its quality, value and momentum, CSL is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a CSL share price forecast 2021?

Shares in CSL are currently priced at A$270.88. At that level they are trading at 17.13% discount to the analyst consensus target price of 0.00.

Analysts covering CSL currently have a consensus Earnings Per Share (EPS) forecast of 4.929 for the next financial year.

How can I tell whether the CSL share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CSL. Over the past six months, the relative strength of its shares against the market has been -15.52%. At the current price of A$270.88, shares in CSL are trading at -8.75% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the CSL PE Ratio?

The CSL PE ratio based on its reported earnings over the past 12 months is 41.58. The shares are currently trading at A$270.88.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of CSL?

CSL's management team is headed by:

Brian McNamee - NEC
Robert Cuthbertson - CSO
Greg Boss - EVP
Bruce Brook - NID
Paul Perreault - CEO
Megan Clark - NID
Alan Wills - EVP
Abbas Hussain - NID
William Campbell - EVP
Elizabeth Walker - CHO
Paul McKenzie - COO
Bill Mezzanotte - EVP
Carolyn Hewson - NID
Joy Linton - CFO
Who are the major shareholders of CSL?

Here are the top five shareholders of CSL based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 3.1% (14.1m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 2.72% (12.4m shares)
Vanguard Investments Australia Ltd. Investment Advisor
Percentage owned: 2.26% (10.3m shares)
Vanguard Total International Stock Index Fund Mutual Fund
Percentage owned: 1.47% (6.70m shares)
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund
Percentage owned: 1.17% (5.32m shares)
Similar to CSL
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.